Ali Ugur Uslu1, Adem Kucuk2, Abdullah Icli3, Erkan Cure4, Davut Sakiz5, Sevket Arslan6, Rabia Aydogan Baykara7. 1. Department of Internal Medicine, Yunus Emre State Hospital, Eskisehir, Turkey. 2. Division of Rheumatology, Department of Internal Medicine, Malatya State Hospital, Malatya, Turkey. 3. Department of Cardiology, Necmettin Erbakan University, School of Medicine, Konya, Turkey. 4. Department of Internal Medicine, Recep Tayyip Erdogan University, School of Medicine, Rize, Turkey. 5. Department of Endocrinology and Metabolism, Dışkapı Yıldırım Beyazit Training and Research Hospital, Ankara, Turkey. 6. Division of Allergy and Clinical Immunology, Necmettin Erbakan University, School of Medicine, Konya, Turkey. 7. Department of Physical Medicine and Rehabilitation, Malatya State Hospital, Malatya, Turkey.
Abstract
OBJECTIVE: Systemic lupus erythematosus (SLE) is characterized by chronic inflammation. Plasma atherogenic index (PAI) is a valuable marker for the cardiovascular disease and cardiac risk. The aim of this study was to evaluate the role and clinical use of PAI in atherosclerosis and the cardiac risk in SLE patients. MATERIALS AND METHODS: We included 56 female SLE patients who were selected according to the American College of Rheumatology (1997) diagnosis criteria. Furthermore, we selected age-and body mass index (BMI)-matched 56 female healthy individuals. PAI was measured as a logarithmic value of triglyceride to high-density cholesterol ratio. We used carotid intima media thickness (cIMT) as an inflammatory marker because of its widespread use. The lipid and other biochemical parameters of patient and control groups were examined. RESULTS: The PAI and cIMT values of SLE patients were 0.04±0.23 and 0.78±0.18 mm, respectively. Besides, for the control group, the PAI value was -0.09±0.20 and cIMT value was 0.50±0.15 mm (p=0.002, p<0.001; respectively). There was a strong correlation between cIMT and PAI (r=0.273, p=0.003). According to the multiple logistic regression analysis, we found that PAI value is an independent factor for cIMT in SLE patients (odds ratio: 2.6, 95 % confidence interval; 1.506-4.374; p=0.029). CONCLUSIONS: We determined that PAI can be used as an independent indicator for subclinical atherosclerosis in SLE patients.
OBJECTIVE: Systemic lupus erythematosus (SLE) is characterized by chronic inflammation. Plasma atherogenic index (PAI) is a valuable marker for the cardiovascular disease and cardiac risk. The aim of this study was to evaluate the role and clinical use of PAI in atherosclerosis and the cardiac risk in SLE patients. MATERIALS AND METHODS: We included 56 female SLE patients who were selected according to the American College of Rheumatology (1997) diagnosis criteria. Furthermore, we selected age-and body mass index (BMI)-matched 56 female healthy individuals. PAI was measured as a logarithmic value of triglyceride to high-density cholesterol ratio. We used carotid intima media thickness (cIMT) as an inflammatory marker because of its widespread use. The lipid and other biochemical parameters of patient and control groups were examined. RESULTS: The PAI and cIMT values of SLE patients were 0.04±0.23 and 0.78±0.18 mm, respectively. Besides, for the control group, the PAI value was -0.09±0.20 and cIMT value was 0.50±0.15 mm (p=0.002, p<0.001; respectively). There was a strong correlation between cIMT and PAI (r=0.273, p=0.003). According to the multiple logistic regression analysis, we found that PAI value is an independent factor for cIMT in SLE patients (odds ratio: 2.6, 95 % confidence interval; 1.506-4.374; p=0.029). CONCLUSIONS: We determined that PAI can be used as an independent indicator for subclinical atherosclerosis in SLE patients.
Authors: Sevket Balta; Mustafa Aparci; Cengiz Ozturk; Ali Osman Yildirim; Mustafa Demir; Turgay Celik Journal: Int J Cardiol Date: 2015-11-10 Impact factor: 4.164
Authors: Emin Murat Akbas; Aysu Timuroglu; Adalet Ozcicek; Fatih Ozcicek; Levent Demirtas; Adem Gungor; Nergis Akbas Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: E Ammirati; E P Bozzolo; R Contri; A Baragetti; A G Palini; D Cianflone; M Banfi; P Uboldi; G Bottoni; I Scotti; A Pirillo; L Grigore; K Garlaschelli; C Monaco; A L Catapano; M G Sabbadini; A A Manfredi; G D Norata Journal: Nutr Metab Cardiovasc Dis Date: 2014-02-01 Impact factor: 4.222